文献速递慢性肾脏病

alirocumab在慢性肾脏病患者中的降脂疗效与安全性

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
PubMed 文献 · Kidney Int · 2018-03-08

本研究汇总8项ODYSSEY三期试验,比较alirocumab在eGFR 30-59与≥60 ml/min/1.73 m²高胆固醇血症患者中的疗效与安全性。第24周时,两组LDL-C降幅分别为46.1%-62.2%和48.3%-60.1%,安全性相似。

要点

  • alirocumab在eGFR 30-59患者中LDL-C降幅与肾功能正常者相当。
  • 肾功能受损与否不影响alirocumab的安全性。
  • alirocumab治疗期间肾功能未随时间变化。

核心结论

  • alirocumab在肾功能受损的高胆固醇血症患者中持续降低LDL-C,安全性可比。

研究设计与样本

  • 汇总8项ODYSSEY三期双盲试验的事后疗效分析,共4629例高胆固醇血症患者,治疗24-104周。

主要发现

  • 第24周时,alirocumab组LDL-C降幅在肾功能受损者为46.1%-62.2%,无受损者为48.3%-60.1%。
  • 脂蛋白(a)、非高密度脂蛋白胆固醇等指标降幅相似。
  • 安全性数据在两组间相似。
  • 肾功能未随时间变化。

关键数值与推荐

  • 肾功能受损定义为eGFR 30-59 ml/min/1.73 m²,无受损定义为eGFR≥60 ml/min/1.73 m²。
  • alirocumab给药方案为150 mg或75/150 mg每两周一次,对照为安慰剂或依折麦布。
  • 总体10.1%患者有肾功能受损,超过99%接受他汀治疗。

临床怎么用

  • 对eGFR 30-59且他汀治疗后LDL-C不达标的高胆固醇血症患者,可考虑加用alirocumab。

局限性

  • 事后分析,肾和血脂参数仅基于血清生化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals with chronic kidney disease are at increased risk of premature cardiovascular disease. Among them, many with elevated low-density lipoprotein cholesterol (LDL-C) are unable to achieve optimal LDL-C on statins and require additional lipid-lowering therapy. To study this, we compared the LDL-C-lowering efficacy and safety of alirocumab in individuals with hypercholesterolemia with impaired renal function, defined as eGFR 30-59 ml/min/1.73 m2, to those without impaired renal function eGFR ≥60 ml/min/1.73 m2. A total of 4629 hypercholesterolemic individuals without or with impaired renal function, pooled from eight phase 3 ODYSSEY trials (double-blind treatments of 24-104 weeks), were on alirocumab 150 mg or 75/150 mg every two weeks vs. placebo or ezetimibe. Overall, 10.1% had impaired renal function and over 99% were receiving statin treatment. Baseline LDL-C in alirocumab and control groups was comparable in subgroups analyzed. LDL-C reductions at week 24 ranged from 46.1 to 62.2% or 48.3 to 60.1% with alirocumab among individuals with or without impaired renal function, respectively. Similar reductions were observed for lipoprotein (a), non-high-density lipoprotein cholesterol, apolipoprotein B, and triglycerides. Safety data were similar in both treatment subgroups, regardless of the degree of CKD. Renal function did not change over time in response to alirocumab. This post hoc efficacy analysis is limited by evaluation of alirocumab treatment effects on renal and lipid parameters by serum biochemistry. Thus, alirocumab consistently lowered LDL-C regardless of impaired renal function, with safety comparable to control, among individuals with hypercholesterolemia who nearly all were on statin treatment.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018. PMID: 29526502. doi:10.1016/j.kint.2017.12.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。